Clinical Trial · NCT07924605

PSMA PET/MRI for Predicting and Detecting Prostate Cancer

Overview

The goal of this clinical trial is to see if a drug called 18F-DCFPyL can help find prostate cancer or prostate cancer that has spread to other parts of the body. The main question it aims to answer is: * Can 18F-DCFPyL predict response to therapy; and, * Does 18F-DCFPyL improve detection of early signs of cancer. Participants will undergo PET/MRI scans.

Sponsor

University of Wisconsin, Madison

Phase

Phase 2

ClinicalTrials.gov

NCT07924605

Study contact

Changhee Lee, MD Principal investigator

Drug / Compound

DCFPyL

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Contraindications to MRI or intravenous contrast administration per institutional MRI safety screening including severe kidney disease, prior severe allergic reaction to gadolinium-based contrast, prior nephrogenic systemic fibrosis
  • Histologic confirmation of prostate adenocarcinoma of the prostate gland, with or without evidence of metastases (oligometastatic \<10 sites) on imaging by conventional imaging (MRI, CT, or 99mTc bone scan) or PSMA PET/CT
  • Participants will have i) enrolled on the METANOVA trial or ii) have selected androgen deprivation therapy prior to surgery as their treatment of choice
  • The participant comes to the research visit with a driver or an alternative plan for transportation (e.g. Uber, taxi, etc.).Inclusion Criteria - Sub-study 2:
  • Reevaluation for progression on active surveillance or watchful waiting as manifest by rising PSA and/or change in digital-rectal exam OR
  • Karnofsky performance status of at least 70
  • The participant comes to the research visit with a driver or an alternative plan for transportation (e.g. Uber, taxi, etc.).
  • Prior definitive treatment to the primary prostate cancer or pelvis. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes (HgA1c \> 10), active pituitary or adrenal dysfunction, or psychiatric illness/social situations that would limit compliance with study requirements
  • Newly diagnosed disease with no prior treatment (surgery, radiation or systemic treatment, hormone therapy or chemotherapy) to the primary disease
  • Evidence of visceral or intracranial metastases.
  • Inclusion Criteria - Sub-study 1:
  • Castration resistant prostate cancer (CRPC).
  • General health and anatomy suitable to undergo transrectal ultrasound-MRI fusion biopsy, as determined by SOC, of the identified lesions and standard 12 core sextent biopsy
  • New diagnosis of prostate cancer undergoing additional biopsy evaluation or high clinical suspicion of prostate cancer with elevated and rising PSA level.
  • Participant with prostate cancer undergoing:
  • Participants may have started LHRH agonist or antagonist therapy, and/or androgen receptor signaling inhibitor (ARSI) as long as it was not started more than 30 days before the patient is enrolled on this study
  • The participant has their own prescription for the medication
  • High risk disease (NCCN criteria Gleason 8-10 or PSA\>20) or oligometastatic
  • Unable to lie flat during or tolerate PET/MRI
  • T1c to T2
  • Participant is participating in a concurrent treatment protocol for cancer.
  • Participant receiving any other investigational agents for cancer.
  • Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:
  • Participant on active surveillance or watchful waiting undergoing planned MRI/TRUS prostate biopsy for re-evaluation
  • Contraindications to MRI or intravenous contrast administration per institutional MRI safety screening including severe kidney disease, prior severe allergic reaction to gadolinium-based contrast, prior nephrogenic systemic fibrosis.
  • Participant must have an ECOG performance status ≤ 1.
  • The participant has their own prescription for the medication
  • Any condition that in the opinion of the investigator would preclude participation in this study.
  • Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:
  • Active Crohn's disease or ulcerative colitis despite medical management.
  • Gleason-group (GG) 1 (Gleason score 6), GG2 (Gleason score 3+4) or GG3 (Gleason score 4+3) prostate adenocarcinoma
  • Any PSA permitted
  • Prior pelvic external beam radiation therapy or brachytherapy
  • Meet criteria ranging from very low to intermediate risk group:
  • Unable to lie flat during or tolerate PET/MRI
  • Androgen deprivation therapy for prostate cancer
  • Chemotherapy for prostate cancer

Exclusion

Exclusion criteria not yet provided.